Searching over 5,500,000 cases.


searching
Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.

Spectrum Pharmaceuticals, Inc. v. Sandoz Inc.

United States District Court, D. Nevada

August 19, 2014

SPECTRUM PHARMACEUTICALS, INC., et al, Plaintiffs,
v.
SANDOZ INC., Defendant.

ORDER ON MOTION TO SEAL (DOCKET No. 261).

NANCY J. KOPPE, Magistrate Judge.

Pending before the Court is Plaintiffs' motion to seal. Docket No. 261. The motion seeks to file under seal portions of Plaintiffs' opposition to Defendant's Motion for Summary Judgment (sealed version: Docket No. 252; public version: Docket No. 251), and Exhibits 1 and 5-10 attached to the Declaration of Amanda K. Antons, filed in support of Plaintiffs' opposition to Defendant's Motion for Summary Judgment (sealed version: Docket Nos. 254-260; public version: Docket No. 253).

Plaintiffs represent in their motion that its sole ground for filing the materials under seal is the designation of the materials by Defendant as confidential and/or outside counsel eyes only pursuant to the parties' Protective Order. Docket No. 261, at 2. Therefore, on July 28, 2014, and in compliance with prior instructions from the Court, Defendant filed the Declaration of Anders T. Aannestad in Support of Plaintiffs' motion to seal. Docket No. 263.

I. STANDARD

The Ninth Circuit has held that there is a strong presumption of public access to judicial records. See Kamakana v. City & County of Honolulu, 447 F.3d 1172, 1178 (9th Cir. 2006); Foltz v. State Farm Mut. Auto. Ins. Co., 331 F.3d 1122, 1135 (9th Cir. 2003). A party seeking to file documents under seal bears the burden of overcoming that presumption. Pintos v. Pac. Creditors Ass'n, 605 F.3d 665, 678 (9th Cir. 2010) (quoting Kamakana, 447 F.3d at 1178). Parties "who seek to maintain the secrecy of documents attached to dispositive motions must meet the high threshold of showing that compelling reasons' support secrecy." Kamakana, 447 F.3d at 1180.[1] Those compelling reasons must outweigh the competing interests of the public in having access to the judicial records and understanding the judicial process. Id. at 1178-79; see also Pintos, 605 F.3d at 679 & n.6 (court must weigh "relevant factors, " including the public's interest in understanding the judicial process). The Ninth Circuit has indicated that "compelling reasons' sufficient to outweigh the public's interest in disclosure and justify sealing court records exist when such court files might have become a vehicle for improper purposes, ' such as the use of records to... release trade secrets." Kamakana, 447 F.3d at 1179.

II. ANALYSIS

In his Declaration, Aannestad represents that Exhibit 1 attached to the Declaration of Amanda K. Antons "contains sensitive information relating to Sandoz's Abbreviated New Drug Application (ANDA')... and Sandoz's business practices." Docket No. 263, at 3. Aannestad further represents, however, that it is possible to redact the confidential information while leaving meaningful information available to the public, and attaches a redacted copy as Exhibit A to his Declaration. Id.; Docket No. 263-1. Aannestad submits that the information redacted from Exhibit 1:

includes proprietary, trade secret, business, and technical information that is presently confidential and unavailable to the public including, without limitation, information concerning the manufacture of Sandoz's proposed ANDA product, the composition of Sandoz's proposed ANDA product, and Sandoz's business practices. Disclosure of such information could injure Sandoz's competitive posture, especially given that Sandoz competes in the competitive and time-sensitive generic pharmaceutical industry.

Docket No. 263, at 3.

Aannestad submits in his Declaration that Exhibit 8 attached to the Declaration of Amanda K. Antons "contains sensitive information relating to Sandoz's ANDA... and Sandoz's business practices." Id., at 5. Aannestad further represents, however, that it is possible to redact the confidential information while leaving meaningful information available to the public, and attaches a redacted copy as Exhibit B to his Declaration. Id.; Docket No. 263-2. Aannestad submits that the redacted portions of Exhibit 8 should remain sealed for the same reasons as the reasons submitted for Exhibit 1. Docket No. 263, at 5.

In his Declaration, Aannestad submits that Exhibits 5, 6, 7 and 9 attached to the Declaration of Amanda K. Antons contain sensitive information relating to Sandoz's business practices and the ANDA and asks the Court to seal them without redaction. Id., at 4-5. Aannestad submits that the information in these Exhibits include:

proprietary, trade secret, business, and technical information that is presently confidential and unavailable to the public including, without limitation, information concerning the manufacture of Sandoz's proposed ANDA product, the composition of Sandoz's proposed ANDA product, and Sandoz's specific efforts to obtain United States FDA approval of its proposed ANDA product. Disclosure of such information could injure Sandoz's competitive posture, especially given that Sandoz competes in the competitive and time-sensitive generic pharmaceutical industry.

Id.

In his Declaration, Aannestad submits that the redacted portions of Exhibit 10 attached to the Declaration of Amanda K. Antons "contain sensitive information relating to Sandoz's ANDA No. 203563 and Sandoz's business practices, " and asks that they remain sealed for the same reasons as those he stated for Exhibit 5. Id., at 5. Aannestad further represents that the Court ...


Buy This Entire Record For $7.95

Download the entire decision to receive the complete text, official citation,
docket number, dissents and concurrences, and footnotes for this case.

Learn more about what you receive with purchase of this case.